Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says

Enliven Therapeutics (NASDAQ:ELVN) had its target price lifted by analysts at HC Wainwright from $48.00 to $56.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 44.22% from the stock’s current price.

ELVN has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Mizuho lifted their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.40.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $38.83 on Thursday. The stock has a market cap of $2.32 billion, a PE ratio of -20.88 and a beta of 0.33. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $40.62. The stock’s 50-day moving average is $28.56 and its two-hundred day moving average is $22.97.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, equities research analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Activity

In related news, insider Joseph P. Lyssikatos sold 91,198 shares of Enliven Therapeutics stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.22, for a total value of $2,482,409.56. Following the transaction, the insider owned 765,188 shares in the company, valued at $20,828,417.36. This trade represents a 10.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard A. Heyman sold 9,635 shares of Enliven Therapeutics stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $25.03, for a total transaction of $241,164.05. Following the completion of the transaction, the director owned 25,545 shares in the company, valued at $639,391.35. This trade represents a 27.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 232,180 shares of company stock valued at $6,217,033. 25.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets increased its position in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth approximately $83,000. Quantbot Technologies LP lifted its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $95,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.